Last reviewed · How we verify
ProAgio Dose Levels 4a,5a,6a
At a glance
| Generic name | ProAgio Dose Levels 4a,5a,6a |
|---|---|
| Also known as | ACT50, Gemcitibine |
| Sponsor | ProDa BioTech, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ProAgio Dose Levels 4a,5a,6a CI brief — competitive landscape report
- ProAgio Dose Levels 4a,5a,6a updates RSS · CI watch RSS
- ProDa BioTech, LLC portfolio CI